Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced that a poster examining the effects of TONMYA (cyclobenzaprine HCl sublingual tablets) on fibromyalgia symptoms and physical function will be presented at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain. The congress is scheduled for Oct. 26-30, 2026, in Bangkok, Thailand. The presentation underscores the company's efforts to generate and share clinical evidence for its flagship medicine, which received U.S. Food and Drug Administration approval on Aug. 15, 2025, and was commercially launched in the United States on Nov. 17, 2025.
TONMYA is the first new treatment for fibromyalgia in more than 15 years, according to the company. Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties, and it affects millions of people worldwide. The lack of new therapeutic options for over a decade has left patients with limited choices, making the introduction of a new treatment significant for the pain management community. The upcoming poster at the IASP World Congress will provide healthcare professionals and researchers with insights into how TONMYA impacts both symptoms and physical function, potentially influencing clinical practice and patient care.
Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, the company's CNS commercial infrastructure supports its marketed acute migraine products, Zembrace SymTouch and Tosymra. Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, its CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
The announcement is relevant to investors and industry observers tracking Tonix's progress. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. For a deeper look at Tonix Pharmaceuticals, visit Tonix Pharmaceuticals (NASDAQ: TNXP). The full press release can be viewed at https://ibn.fm/jFHh3.
The news was distributed through TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. For full terms of use and disclaimers, see https://www.TinyGems.com/Disclaimer.
